Human iPS Cells Derived Cardiomyocytes

The world’s first commercial human iPSC-derived cardiomyocytes (launched in April 2009)

Cardiotoxicity is one of the major concerns for all new clinical compounds. To address this concern and the trend toward animal-free testing, ReproCELL became the world’s first commercial provider of human iPS cell-derived cardiomyocytes and services (since 2008). Called QTempo, this service (available in Japan) is an in vitro safety pharmacology assay service using beating cardiomyocytes derived from iPS cells. Furthermore, ReproCELL’s cardiomyocyte products and services can be flexibly tailored to the customers’ needs by genetic manipulation, use of patient-derived source material, or other collaborations. Today, ReproCELL is a recognized leader in cardiomyoctye applications and tools for research and development.

Reagents for human iPS cell-derived cardiomyocytes

Product Name and Description


– Frozen cardiomyocytes derived from iPS cells – Expresses cardiac ion channels and cardiomyocyte-specific markers


ReproCardio2 Assay Medium

Assay medium specially developed for electrophysiological and optical recordings from cardiomyocytes

Assay service with human iPS cell-derived cardiomyocytes (available in Japan)

Product Name and Description

QTempo assay service

Assay service of cardiotoxicity and comprehensive analysis of cardiac ion channels using human iPS cell-derived beating cardiomyocyte clusters

Find a distributor for your country